Drug Discovery World

APRIL 26, 2024

In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. This means the vaccine can target the mutations unique to each patient’s tumour.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

OCTOBER 10, 2023

By analysing gene interactions in mice subjected to behavioural tests, the researchers from Korea University Anam Hospital, Konkuk University, and Sahmyook University identified 141 genes primarily linked to immune responses correlating with depressive behaviours.

Immune Response 147

Immune Response FDA Approval Drugs DNA 147

Drug Discovery World

JANUARY 18, 2024

POLB 001 has been shown to reduce hyperinflammation without complete ablation of an effective immune response, which makes it potentially a very attractive therapy for this disease area. If there was a therapy that was orally delivered, a whole lot of infrastructure requirement falls away.”

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

MARCH 13, 2023

The data confirms the good overall safety profile of the product in terms of systemic and ocular tolerability, humoral and cellular immune response. The results also highlight a comparable safety profile for unilaterally and bilaterally treated patients.

Therapies 130

Therapies Immune Response Hospitals Treatment 130

Drug Discovery World

MAY 30, 2024

The Experimental Medicine Clinical Research Facility is a collaboration between the University of Oxford and the Oxford University Hospitals NHS Foundation Trust. It is these differences in immune response, which have stimulated our research to improve vaccine design.

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

Drug Discovery World

JANUARY 17, 2023

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. . The trial . Official comments .

Clinical Trials 130

Clinical Trials Trials Drug Development Hospitals 130

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) In addition, the T-cell responses are especially strong and stable over time, which is also potentially important for activity against these variants.”.

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

Drug Discovery World

MARCH 27, 2023

The concept of a vaccine for cholesterol could be a game-changer in cardiovascular health due to its potentially very broad reach and impact on human health,” said Professor Stephen Nicholls of Monash University and Victorian Heart Hospital in Australia.

Vaccine 130

Vaccine Immune Response Trials Clinical Trials 130

Drug Discovery World

JUNE 13, 2023

This interaction activates the complement system, which plays a key role in the innate immune response but, when dysregulated, contributes to the development of numerous diseases. During HD, blood interacts with the biomaterials of the HD circuit.

Immune Response 130

Immune Response Hospitals Disease Therapies 130

Drug Discovery World

AUGUST 2, 2023

This led us to investigate if targeting palmitoylation could be a potential strategy for modulating PD-L1 expression and enhancing anti-tumour immune responses. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng 2019;3:306-317. Yang Y, Hsu JM, Sun L, et al.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 104

Bioinformatics Immune Response DNA Vaccine 104

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Discovery World

JULY 29, 2022

Isselbacher Professor of Medicine in the Field of Gastroenterology at Harvard Medical School and Massachusetts General Hospital, a core institute member at the Broad Institute of MIT and Harvard, and co-director of the Center for Microbiome Informatics and Therapeutics at MIT. muciniphila’s cell membrane. That discovery was quite surprising.

Research 130

Research Immune Response Medical Schools Disease 130

The Pharma Data

MARCH 8, 2022

However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. In this way, the viral RNA escapes early recognition by the central antiviral immune-receptor RIG-I. Researchers led by Prof. For example, viral RNAs are masked by the addition of a methyl group.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

AUGUST 19, 2021

Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date. Source link: [link].

Vaccine 52

Vaccine Immune Response Hospitals FDA 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 23, 2021

A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses. But even though the protection isn’t absolute, cross-reactive immune responses shorten the infection and reduce its severity.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

JANUARY 5, 2021

” The clinical trial involved 24 COVID patients at one of two Miami-area hospitals who had developed severe acute respiratory distress syndrome, a condition in which the body’s immune response to a serious infection causes the lungs to fill with fluid. The stem cells also sped recovery time.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. In early April, Nussenzweig’s team began analyzing samples from volunteer survivors who visited The Rockefeller Hospital to donate plasma, which contains the antibodies.

Immune Response 52

Immune Response Virus Vaccine Research 52

Drug Discovery World

OCTOBER 21, 2022

New research has identified immune targets for chemotherapy-resistant breast cancers. The research sheds light on the function of immune cells in these patients and will help future studies to enhance the anti-cancer immune response in breast cancer. Discovery of invasive dormant cancer cells.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. government for up to 100,000 doses ( DID, Dec. 28, 2020 ). government for up to 100,000 doses ( DID, Dec. 28, 2020 ).

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins.

Vaccine 52

Vaccine Immune Response Virus International 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 117

Therapies Cell Biology Clinical Trials Trials 117

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

AUGUST 24, 2020

Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. The strongest immune response has been found in the most seriously ill patients. But it is still not clear how strong this protection or immunity is – or how long it lasts.

Virus 52

Virus Immune Response Hospitals Vaccine 52

The Pharma Data

NOVEMBER 22, 2020

The treatment was authorized for use in mild to moderate COVID-19 patients age 12 and above, who have tested positive for the virus and are at high risk for progressing to severe COVID-19 and/or hospitalization.

Immune Response 52

Immune Response Virus Hospitals Government 52

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. muciniphila ’s cell membrane. That discovery was quite surprising.

Research 52

Research Immune Response Medical Schools Disease 52

Drug Discovery World

MAY 6, 2024

In Paris itself, Institut Curie is a major cancer hospital, from which One Biosciences was spun-off. Beyond this specific plan, France has a strong policy to support innovation with research tax credits and specific programmes. For instance, One Biosciences has already received €2 million in non-dilutive financing.”

Drugs 147

Drugs Molecular Biology Science Clinical Trials 147

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. This is then given to patients, immediately boosting their immune response. The UK Recovery Trial was set up at the start of the pandemic to identify treatments that could help people admitted to hospital with Covid-19. Image copyright.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Applicability of the technology has also been demonstrated for additional infectious disease pathogens, including those that cause hospital-acquired infections.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Applicability of the technology has also been demonstrated for additional infectious disease pathogens, including those that cause hospital-acquired infections.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

LifeSciVC

JULY 1, 2024

There is a huge panoply of careers for those interested in science – ranging from the lab, to the hospital, to the office; staying open-minded across a wide range of pursuits will give you a better foundation than a narrow focus. Build your social immunity. Focus on phenotypes, not genotypes.

Science 74

Science Immune Response Molecular Biology RNA 74